Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 20/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539325 | 1.00 | OPRL1 (0.77) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3543309 | 0.87 | OPRL1 (1.00) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3541425 | 0.85 | OPRL1 (0.79) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3547319 | 0.85 | OPRL1 (0.79) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3540877 | 0.80 | OPRL1 (1.00) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3543493 | 0.80 | OPRL1 (0.87) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3543491 | 0.80 | OPRL1 (0.87) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3540469 | 0.77 | OPRL1 (1.00) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3544004 | 0.76 | OPRL1 (0.77) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3541721 | 0.76 | OPRL1 (0.79) | OPRL1KCNH2OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
| US-10723703-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-10183913-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-22 | — | — | US | disclosed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20140315971-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2014-10-23 | — | — | US | disclosed |
| US-8809383-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008528-A1 | PYRAZOLE COMPOUND | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315971-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | OPRL1 124/4885KCNH2 353/4885OPRK1 119/4885 |
| US-10183913-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | OPRL1 124/4885KCNH2 353/4885OPRK1 119/4885 |
| US-20170217902-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | OPRL1 124/4885KCNH2 353/4885OPRK1 119/4885 |
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | OPRL1 124/4885KCNH2 353/4885OPRK1 119/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | OPRL1 124/4885KCNH2 353/4885OPRK1 119/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | OPRL1 124/4885KCNH2 353/4885OPRK1 119/4885 |
| US-10723703-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | OPRL1 124/4885KCNH2 353/4885OPRK1 119/4885 |
| US-20190084938-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | OPRL1 124/4885KCNH2 353/4885OPRK1 119/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | OPRL1 124/4885KCNH2 353/4885OPRK1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.